

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29<sup>th</sup> May, 2017

**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today 29<sup>th</sup> May, 2017 has, inter alia, approved the Audited Financial Results of the Company for Quarter & Year ended 31<sup>st</sup> March, 2017.

Enclosed please find herewith the following

1. Audited financial results of the Company for the financial year ended 31<sup>st</sup> March, 2017 and the financial results of the Company in respect of the fourth quarter of FY 2016-17.
2. Statement of Assets and Liabilities.
3. The Auditors Report,
4. Declaration from the Company for Audit Report is of 'Unmodified Opinion',

The aforesaid result and report are attached for your record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

  
(Jyoti Sancheti)  
Company Secretary & Compliance Officer



Encl.: As above

**BROOKS LABORATORIES LIMITED**  
 Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101  
 CIN NO: L24232HP2002PLC000267

Tel No : +91 1795 654001/02/03, Fax No :+91 1795 236939, E-mail : investors@brookslabs.net, Website: www.brookslabs.net  
 Audited Financial Results for the Quarter/ Year Ended March 31, 2017

**PART I**

Particulars	Quarter Ended			Year Ended	Year ended
	31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1 Income from operations</b>					
(a) Net sales	1,627.96	1,647.48	2,069.33	6,484.30	8,000.94
<b>Total income from operations (net)</b>	<b>1,627.96</b>	<b>1,647.48</b>	<b>2,069.33</b>	<b>6,484.30</b>	<b>8,000.94</b>
<b>2 Expenses</b>					
(a) Cost of materials consumed	974.39	1,004.50	1,248.42	3,664.91	5,259.55
(b) Changes in inventories of finished goods & work-in-progress	63.32	(87.94)	29.77	1.35	34.68
(c) Employee benefits expense	236.42	201.76	204.23	820.94	707.84
(d) Depreciation and amortisation expense	69.81	33.51	29.15	167.20	116.00
(e) Excise Duty (Refer Note 3)	195.70	239.60	-	730.32	-
(f) Other Expenses	185.86	162.97	212.01	704.78	890.53
<b>Total expenses</b>	<b>1,725.50</b>	<b>1,554.40</b>	<b>1,723.58</b>	<b>6,089.50</b>	<b>7,008.60</b>
<b>3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(97.56)</b>	<b>93.08</b>	<b>345.75</b>	<b>394.80</b>	<b>992.34</b>
4 Other income	4.92	3.94	21.76	12.27	156.10
<b>5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>(92.64)</b>	<b>97.02</b>	<b>367.51</b>	<b>407.07</b>	<b>1,148.44</b>
6 Finance costs	32.52	25.35	10.16	100.94	79.44
<b>7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)</b>	<b>(125.16)</b>	<b>71.67</b>	<b>357.35</b>	<b>306.13</b>	<b>1,069.00</b>
8 Exceptional items / Prior period items	-	-	12.88	-	12.88
<b>9 Profit / (Loss) from ordinary activities before tax (7 - 8)</b>	<b>(125.16)</b>	<b>71.67</b>	<b>370.23</b>	<b>306.13</b>	<b>1,081.88</b>
10 Tax expense					
- Current tax	(21.28)	14.61	99.71	66.61	242.06
- MAT credit (Entitlement)/Utilised	(101.48)	4.08	(78.79)	(62.37)	(184.88)
- MAT credit (Entitlement) of earlier year	-	-	(60.39)	-	(60.39)
- Deferred tax	86.04	5.35	10.10	101.91	13.21
- Tax of earlier years	-	-	(62.75)	4.32	8.55
<b>11 Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>(88.44)</b>	<b>47.63</b>	<b>462.35</b>	<b>195.66</b>	<b>1,063.33</b>
12 Extraordinary items	-	-	-	-	-
<b>13 Net Profit / (Loss) for the period (11 + 12)</b>	<b>(88.44)</b>	<b>47.63</b>	<b>462.35</b>	<b>195.66</b>	<b>1,063.33</b>
14 Paid-up equity share capital (Face Value Rs.10/- per share)	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	10,586.37	10,586.37	9,523.04	10,586.37	9,523.04
16.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):					
(a) Basic -in Rs.	(0.55)	0.29	2.86	1.21	6.57
(b) Diluted- in Rs.	(0.55)	0.29	2.86	1.21	6.57
16.ii Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):					
(a) Basic -in Rs.	(0.55)	0.29	2.86	1.21	6.57
(b) Diluted- in Rs.	(0.55)	0.29	2.86	1.21	6.57

**Notes:**

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 29, 2017.
- During the month of March 2017, company has commenced its commercial production of Vadodara unit, first sale invoice of vadodara unit is raised in April, 2017
- W.e.f 2nd June 2016, excise duty has been levied on the product manufactured at baddi unit at Himachal Pradesh which was exempted earlier by central government being backward state.
- The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).

**For Brooks Laboratories Ltd.**

**Managing Director**

DIN No. 02000634

- 5 The figures of the last quarter ended March 31, 2017 and March 31, 2016 are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the relevant financial year.
- 6 Figures of the previous period / year have been reclassified/ regrouped wherever necessary.

Date : May 29, 2017  
Place : Mumbai

For and on behalf of the Board

  
Rajesh Mahajan  
DIN No. : 02000634  
Managing Director

**Brooks Laboratories Limited**

**Statement of Assets and Liabilities as on March 31, 2017**

(Rs. in Lacs)

Particulars	Year ended	Year ended
	31.03.2017	31.03.2016
	(Audited)	(Audited)
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	1,618.64	1,618.64
(b) Reserves and surplus	10,782.02	10,586.37
<b>Sub-total - Shareholders' funds</b>	<b>12,400.66</b>	<b>12,205.01</b>
<b>2 Non-current liabilities</b>		
(a) Long-term borrowings	1,080.51	34.24
(b) Deferred tax liabilities (net)	248.02	146.10
(c) Long-term provisions	97.54	76.18
<b>Sub-total - Non-current liabilities</b>	<b>1,426.07</b>	<b>256.52</b>
<b>3 Current liabilities</b>		
(a) Short-term borrowings	217.55	528.36
(b) Trade payables	1,836.40	1,571.60
(c) Other current liabilities	351.70	561.32
(d) Short-term provisions	76.80	130.87
<b>Sub-total - Current liabilities</b>	<b>2,482.45</b>	<b>2,792.15</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>16,309.18</b>	<b>15,253.68</b>
<b>B ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Fixed assets	11,858.96	10,319.39
(b) Non-current investments	2.00	2.00
(c) Long-term loans and advances	2,047.40	1,938.28
<b>Sub-total - Non-current assets</b>	<b>13,908.36</b>	<b>12,259.67</b>
<b>2 Current assets</b>		
(a) Inventories	769.89	668.89
(b) Trade receivables	1,149.17	1,891.44
(c) Cash and cash equivalents	183.69	222.58
(d) Short-term loans and advances	286.96	189.33
(e) Other current assets	11.11	21.77
<b>Sub-total - Current assets</b>	<b>2,400.82</b>	<b>2,994.01</b>
<b>TOTAL - ASSETS</b>	<b>16,309.18</b>	<b>15,253.68</b>

For Brooks Laboratories Ltd.

*[Signature]*  
Managing Director

DIN No. 02000634

# **SGCO & Co. LLP**

Chartered Accountants

## **Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To The Board of Directors of  
Brooks Laboratories Limited**

1. We have audited the accompanying statement of Financial Results of Brooks Laboratories limited ("the Company") for the quarter ended March 31, 2017 and year to date results for the period from April 1, 2016 to March 31, 2017 attached herewith ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under section 133 of The Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether statement is free from material misstatement.  
An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatements in the accompanying Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness on the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the Statement.  
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
3. In our opinion and to the best of our information and according to explanation given to us ,the statement;
  - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015; and
  - (ii) Gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial Information of the Company for the year ended 31<sup>st</sup> March 2017.

4A, Kaledonia-HDIL,  
2<sup>nd</sup> Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069. India

Tel.: +91 22 6625 6363  
Fax: +91 22 6625 6364  
E-mail: info@sgco.co.in  
www.sgco.co.in



**SGCO & Co. LLP**

Chartered Accountants

4. The statement includes the results for the quarter ended 31<sup>st</sup> March 2017 being the balancing figure between the audited figures in respect of the full financial year and the published year to dated figures up to the third quarter of the current financial year which were subject to limited review by us.

**For SGCO & Co. LLP**

Chartered Accountants

**Firm's Registration No.112081W/W100184**



**Shyamratan Singrodia**

Partner

**Mem. No. 49006**

Place : Mumbai

Date: 29<sup>th</sup> May, 2017

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29<sup>th</sup> May, 2017

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Scip Code: **533543**

Symbol: **BROOKS**

**Sub: Declaration by the Company for Auditors Unmodified opinion on the Audited Financials Results for the year ended 2016-17**

Dear Sirs,

This has reference to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016 regarding disclosure of the Impact of Audit Qualifications by the Listed Companies.

We hereby declare that the Audit Report for the Annual Audited Financial Results for the year ended 31.03.2017 is of '**Unmodified Opinion**'.

Kindly take the same on record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

  
(Rajesh Mahajan)

Managing Director

DIN No.: 02000634

